C
Courtney L. Sutphen
Researcher at Washington University in St. Louis
Publications - 22
Citations - 2269
Courtney L. Sutphen is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Alzheimer's disease & Biomarker (medicine). The author has an hindex of 12, co-authored 19 publications receiving 1681 citations.
Papers
More filters
Journal ArticleDOI
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Yang Shi,Kaoru Yamada,Shane A. Liddelow,Shane A. Liddelow,Scott T. Smith,Lingzhi Zhao,Wenjie Luo,Richard M. Tsai,Salvatore Spina,Lea T. Grinberg,Julio C. Rojas,Gilbert Gallardo,Kairuo Wang,Joseph Roh,Grace O. Robinson,Mary Beth Finn,Hong Jiang,Patrick Sullivan,Caroline Baufeld,Michael W. Wood,Courtney L. Sutphen,Lena McCue,Chengjie Xiong,Jorge L. Del-Aguila,John C. Morris,Carlos Cruchaga,Alzheimer's Disease Neuroimaging Initiative,Anne M. Fagan,Bruce L. Miller,Adam L. Boxer,William W. Seeley,Oleg Butovsky,Ben A. Barres,Steven M. Paul,David M. Holtzman +34 more
TL;DR: It is demonstrated that ApoE affects tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-β pathology.
Journal ArticleDOI
Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels.
Yo-El Ju,Sharon Ooms,Courtney L. Sutphen,Shannon L. Macauley,Margaret A. Zangrilli,Gina Jerome,Anne M. Fagan,Emmanuel Mignot,John M. Zempel,Jurgen A.H.R. Claassen,David M. Holtzman +10 more
TL;DR: Slow wave activity disruption increases amyloid-β levels acutely, and poorer sleep quality over several days increases tau, which suggests they are likely driven by changes in neuronal activity during disrupted sleep.
Journal ArticleDOI
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age
Courtney L. Sutphen,Mateusz S. Jasielec,Aarti R. Shah,Elizabeth M. Macy,Chengjie Xiong,Andrei G. Vlassenko,Tammie L.S. Benzinger,Erik Stoops,Hugo Vanderstichele,Britta Brix,Heather Darby,Manu Vandijck,Jack H. Ladenson,John C. Morris,David M. Holtzman,Anne M. Fagan +15 more
TL;DR: Longitudinal CSF biomarker patterns consistent with AD are first detectable during early middle age and are associated with later amyloid positivity and cognitive decline, useful for targeting middle-aged, asymptomatic individuals for therapeutic trials designed to prevent cognitive decline.
Journal ArticleDOI
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
Catherine M. Roe,Anne M. Fagan,Elizabeth A. Grant,Jason Hassenstab,Krista L. Moulder,Denise Maue Dreyfus,Courtney L. Sutphen,Tammie L.S. Benzinger,Mark A. Mintun,David M. Holtzman,John C. Morris +10 more
TL;DR: The results indicate that all AD biomarkers studied here predicted incident cognitive impairment, and support the hypothesis that biomarkers signal underlying AD pathology at least several years before the appearance of dementia symptoms.
Journal ArticleDOI
Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo
Shannon L. Macauley,Molly Stanley,Emily E. Caesar,Steven A. Yamada,Marcus E. Raichle,Ronaldo Perez,Thomas E. Mahan,Courtney L. Sutphen,David M. Holtzman +8 more
TL;DR: Results suggest that K(ATP) channel activation mediates the response of hippocampal neurons to hyperglycemia by coupling metabolism with neuronal activity and ISF Aβ levels.